2 genes

- 3 Peter Saliba-Gustafsson^{1-4*}, Johanne M. Justesen^{1,5*}, Amanda Ranta^{1,3,4}, Disha Sharma^{1,4}, Ewa Bielczyk-Maczynska^{1,3,4,6}, Jiehan
- 4 Li^{1,3,4}, Laeya A. Najmi^{1,3,4}, Maider Apodaka⁷, Patricia Aspichueta⁷⁻⁸, Hanna M. Björck⁹, Per Eriksson⁹, Anders Franco-Cereceda¹⁰,
- 5 Mike Gloudemans¹¹, Endrina Mujica¹², Marcel den Hoed¹², Themistocles L. Assimes^{1,13}, Thomas Quertermous^{1,5}, Ivan Carcamo-
- 6 Orive^{1,14}, Chong Y. Park¹, Joshua W. Knowles^{1,3,4,15#}
- 7 *Contributed equally to this work
- 8 *Corresponding author
- 9 1. Department of Medicine, Division of Cardiovascular Medicine and Cardiovascular Institute, Stanford University, Stanford,
- 10 CA, USA

- 11 2. CardioMetabolic Unit at the Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden
- 3. Stanford Diabetes Research Center, Stanford, CA, USA
- 4. Stanford Cardiovascular Institute, Stanford University School of Medicine, CA, USA
- 14 5. Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Denmark
- 15 6. The Hormel Institute, University of Minnesota, MN, USA
- 16 7. University of the Basque Country (UPV/EHU), Faculty of Medicine and Nursing, Department of Physiology, Leioa, Spain
- 17 8. National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Instituto de Salud Carlos III)
- 9. Division of Cardiovascular Medicine, Centre for Molecular Medicine, Department of Medicine, Solna, Karolinska Inistitutet,
- 19 Stockholm, Karolinska University Hospital, Solna, Sweden
- 20 10. Department of Molecular Medicine and Surgery, Karolinska Inistitutet, Stockholm, Sweden
- 21 11. Department of Pathology, Stanford University School of Medicine, CA, USA
- 22 12. Department of Immunology, Genetics and Pathology, Uppsala University, Sweden
- 23 13. VA Palo Alto Health Care System, Palo Alto CA, USA
- 24 14. IKERBASQUE, Basque Foundation for Science, Bilbao, Spain.
- 25 15. Stanford Prevention Research Center, Stanford, CA, USA
- **Keywords:** NAFLD, CRISPR interference, genetic epidemiology, Perturb-seq, HepaRG cells
- 27 Contact information: Joshua W. Knowles
- 28 Falk Cardiovascular Research Center

29 870 Quarry Road Extension 30 31 Stanford, CA 94305 knowlej@stanford.edu 32 List of Abbreviations: 33 34 Financial Support: PSG is supported by the Swedish Research Council (Vetenskapsrådet), grant number 2018-06580 and the 35 Swedish Heart-Lung Foundation grant number 20170221. JMJ is funded by grants from the Novo Nordisk Foundation and the 36 Stanford Bio-X Program (NNF17OC0025806). JWK is supported by the NIH through grants: P30 DK116074 (to the Stanford 37 Diabetes Research Center), R01 DK116750, R01 DK120565, R01 DK106236; and by the American Diabetes Association through 38 grant 1-19-JDF-108. AR is supported by the Finnish Foundation for Cardiovascular Research, Diabetes Research Foundation, Emil 39 Aaltonen Foundation, Ida Montin's Foundation, Biomedicum Helsinki Foundation, Orion Research Foundation and the Finnish 40 Medical Foundation. The ASAP study was supported by the Swedish Research Council grant number 2020-01442, the Swedish 41 Heart-Lung Foundation grant number 20180451 and a donation by Mr. Fredrik Lundberg. PA is supported by MCIU/AEI/FEDER, 42 UE (PID2021-124425OB-I00) and Basque Government, Department of Education (IT1476-2). 43

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

3

Abstract Background & Aims Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver pathology in western countries, with serious public health consequences. Efforts to identify causal genes for NAFLD have been hampered by the relative paucity of human data from gold-standard magnetic resonance quantification of hepatic fat. To overcome insufficient sample size, genome-wide association studies using NAFLD surrogate phenotypes have been used, but only a small number of loci have been identified to date. In this study, we combined GWAS of NAFLD composite surrogate phenotypes with genetic colocalization studies followed by functional in vitro screens to identify bona fide causal genes for NAFLD. Approach & Results We used the UK Biobank to explore the associations of our novel NAFLD score, and genetic colocalization to prioritize putative causal genes for in vitro validation. We created a functional genomic framework to study NAFLD genes in vitro using CRISPRi. Our data identify VKORC1, TNKS, LYPLAL1 and GPAM as regulators of lipid accumulation in hepatocytes and suggest the involvement of VKORC1 in the lipid storage related to the development of NAFLD. Conclusions Complementary genetic and genomic approaches are useful for the identification of NAFLD genes. Our data supports VKORC1 as a bona fide NAFLD gene. We have established a functional genomic framework to study at scale putative novel NAFLD genes from human genetic association studies.

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

4

Introduction Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver condition, with serious public health consequences. Globally, at least 25% of adults are estimated to suffer from NAFLD, and cardiovascular disease is the leading cause of death among these patients. (1, 2) NAFLD displays a wide spectrum of liver pathology, ranging from nonalcoholic fatty liver, which is typically benign, to nonalcoholic steatohepatitis (NASH), characterized by steatosis and features of cellular injury, such as inflammation and hepatocyte ballooning. NASH may progress to liver cirrhosis, hepatic failure, and hepatocellular carcinoma in the absence of significant alcohol consumption. The degree of steatosis can be measured through various imaging techniques but the gold standard of these is abdominal magnetic resonance imaging (MRI). However, abdominal MRI is not typically conducted on asymptomatic individuals, often leaving NAFLD undiagnosed for years. Genome-wide association studies (GWAS) have been used to identify associations between NAFLD and common genetic variants. Due to the scarcity of MRI data, identifying risk loci for NAFLD has been slower than for other cardiometabolic diseases or their risk factors (e.g., body mass index (BMI)) or biochemical measures (e.g., serum liver enzymes and lipids levels), and other complex cardiometabolic diseases such as obesity, and diabetes. One way to overcome the challenge of data scarcity in NAFLD is to comprise latent proxies for NAFLD using data that is more readily available in large cohort studies. For instance, Bedogni et al. (3) established the fatty liver index (FLI) as a surrogate variable for NAFLD; however, FLI did not outperform waist circumference in predicting NAFLD in a validation study. (4) Aiming to increase our understanding of the molecular etiology of NAFLD, we here generate (NAFLD-S), a composite variable of anthropometric and biochemical variables to predict liver fat. By using an alternative surrogate to predict liver fat, and running GWAS combined with genetic colocalization, we identify novel loci associated with NAFLD. The use of genetic colocalization aids in inferring causality

and serves to prioritize genes for functional follow-up. We use CRISPR-interference (CRISPRi) to

interrogate the impact of multiple genes on both transcriptional changes and functional phenotypes, at a single-cell level. (5–9) We characterize a subset of putative NAFLD genes *in vitro* and *in vivo* through an integrated framework and identify *VKORC1* as a likely causal NAFLD gene.

Experimental procedures

Study population

This research was conducted using UK Biobank (UKB) data under application number 13721. The UKB is a cohort of over 500,000 adults that has tracked health behaviors, anthropometric measurements, and medical history. Biological samples that have been acquired longitudinally since the subjects' enrollment in 2006-2010. A subset of white British participants in the UKB was utilized in the current study, a sub-population which has been described in detail (10). Briefly, we excluded individuals who withdrew consent (n=167), and those who reported excessive alcohol consumption (n=128,477), which was defined as weekly alcohol consumption of ≥140 grams for women and ≥210 grams for men as per prevailing European guidelines (11). Further, we excluded those with other known liver diseases, alcohol use disorder, and HIV infection based on ICD-9 and ICD-10 codes (n=3,022). Individuals with short-term poor prognosis including diagnosis of metastatic cancer within one year of the baseline visit and palliative care or hospice status based on ICD-9 and ICD-10 codes were also excluded (n=4,497). After exclusions 242,524 individuals remained, whose characteristics have been described (10). The UKB study was approved by the Northwest Multi-Center Research Ethics Committee and all participants provided written informed consent to participate. The UKB study protocol is available online (12).

Generating the NAFLD score in UKB

In the UKB, true NAFLD cases were first identified using existing data on liver fat from MRI (data fields 22402, 22436 and 24352). Individuals with a liver fat percent $\geq 5.5\%$ were considered to have NAFLD, which resulted in a population of 2,544 NAFLD cases and 10,168 controls. The 5.5% cut-off is higher than the 5% convention, but motivated to reduce the risk of measurement error impacting the results. We utilized

biochemical and anthropometric data to determine a NAFLD score in the full subset of 242.524 participants in the UKB. Briefly, we performed a multivariate logistic regression analysis to estimate effect sizes of the biochemical and anthropometric predictors of liver fat percentage from MRI data. Table 1 shows the variables included in the prediction models and their effect sizes. We constructed a NAFLD score for the subset of UKB, as well as calucated the fatty liver index (FLI) (3), the difference lies in that the NAFLD score includes more predictors of liver fat from MRI than the FLI (see equation 1 below). The score was derived by multiplying the value for each biochemical and anthropometric trait with its effect size (beta), and then rounded to the nearest integer between 0 and 100 (Equation 1). The NAFLD score was compared with FLI, alanine aminotransferase (ALT), triglycerides (TG), gamma-glutamyl transpeptidase (GGT) and BMI in predicting liver fat percentage using a receiver operating characteristic (ROC) curve. Ultimately, the NAFLD score was used as the surrogate for NAFLD to conduct a GWAS in 242,524 participants in the UKB. **Equation 1 NAFLD score** = $(e^{(-0.52707 \times sex + 0.45029 \times Triglycerides + 0.06973 \times BMI + 0.06514 \times GGT + 0.53716 \times BMI + 0.06514 \times GGT + 0.53716 \times BMI + 0.06514 \times GGT + 0.06514 \times GG$ Waist Circumference + $(-0.14647 \times Cholesterol)$ + $0.15941 \times AST$ + $0.15286 \times HbA1c$ + $(-0.40867 \times AST/ALT)$ + $0.17569 \times HbA1c$ + $(-0.40867 \times AST/ALT)$ + (-0.40867Albumin) - 3.20145)/(1 + (e^(-0.52707 × sex + 0.45029 × Triglycerides + 0.06973 × BMI + 0.06514 × GGT + 0.53716 × Waist Circumference + $(-0.14647 \times Cholesterol)$ + $0.15941 \times AST$ + $0.15286 \times HbA1c$ + $(-0.40867 \times AST/ALT)$ + $0.17569 \times HbA1c$ + $(-0.40867 \times AST/ALT)$ + (-0.40867 $Albumin) - 3.20145) \times 100$ Genome-wide association analyses Genome-wide association analyses (GWAS) were carried out using both the generated NAFLD score as a continuous variable (NAFLD-S), ALT, and NAFLD status from MRI (MRI UKB) in 242,524 white Brits with an at most moderate alcohol consumption. Analyses were carried out in Plink 2, and were adjusted for age, sex, genotyping batch and the first 10 genetic principal components. Imputed SNPs with INFO<0.8

were excluded, and dependent SNPs were pruned out using a 50kb window and a R^2 threshold of 0.8.

Genetic colocalization analyses

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

SNPs associated with either cALT (chronic ALT), ALT (one point measurement), ALP, GGT, NAFLD score or NAFLD status from MRI were tested for genetic colocalization using the GTEx (v8) eQTL and sQTL data in metabolically relevant tissues (liver, subcutaneous adipose tissue, visceral adipose tissue, skeletal muscle and pancreas). Briefly, summary statistics from previously conducted GWASes (cALT, ALP, GGT) were obtained, and integrated with the GWASes conducted herein (NAFLD-S, ALT and NAFLD status). The colocalization analyses compute the probability that genetic association signals for trait and a QTL feature are produced by a common causal variant, as well as gene-level colocalizations. We used a novel, in-house, custom integration of the FINEMAP (13) and eCAVIAR (14) methods, which has been described in detail (15), to calculate gene-level colocalization scores. Genome-wide significance threshold was determined as 5e-8 in all except the two MRI GWASes where the significance threshold was set at 1e-5. QTL threshold was set at 1e-5. A colocalization score of 0.35 or above was considered as a coloc. All colocalizations were then investigated for gene set enrichment using GSEA (http://www.gseamsigdb.org/gsea/index.isp), to elucidate pathways that are disturbed in NAFLD.

Cellular model

The HepaRGTM cell line (Sigma Aldrich) was established from a tumor of a female patient suffering from chronic hepatitis C (HVC) infection and hepatocarcinoma. HepaRGTM cells do not contain any part of the HCV genome nor express any HCV protein. (16–18). *In vitro*, maximum cell differentiation is reached when cells are exposed to 2 weeks of differentiation media 14 days after seeding, and 40 to 50% of the confluent cell population is hepatocyte-like in nature, with a morphology close to that of primary human hepatocytes (PHHs). A genome-wide gene expression profile analysis showed that for most genes encoding phase 1 and 2 drug metabolizing enzymes and drug transporters, the differences between HepaRGTM cells and PHHs were much smaller than between HepG2 cells and PHHs. (19)

Generation, characterization, and validation of a HepaRG cell line suitable for gene editing

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

9

infection (MOI) of 0.10-0.15, HepaRG cells were transduced with serial dilutions of lentiviral stock in the presence of 8 ug/ml polybrene, cultured for two days, and analyzed for blue fluorescent protein (BFP) using flow cytometry. *CRISPRi screens and Perturb-seq experiments* On the day of the single-cell capture (day 42 of HepaRG cell culturing), cells were trypsinized, strained, and stained with the live/dead stain SYTOX Green Ready Flow Reagent (Thermo Fisher), according to the manufacturer's protocol. Cells were kept on ice throughout. Live (SYTOX-negative), BFP/mCherry+/+ single cells were isolated using FACS at the Stanford Shared FACS Facility. Next, live, gene-edited cells underwent microfluidic single-cell capture on the 10X Chromium Controller device at the Stanford Genomics Service Center. In brief, single cells were encapsulated with individual Gel Beads-in-emulsion (GEMs) using the Chromium Next GEM Single Cell 3' GEM, Library & Gel Bead Kit with the CRISPR feature barcodes technology (10X Genomics). In-drop reverse transcription and cDNA amplification were conducted according to the manufacturer's protocol to construct expression and feature barcode libraries. Library quality control was carried out using an Agilent Bioanalyzer 2100. Expression libraries were sequenced on an Illumina NovaSeq 6000 sequencer. Validation experiments confirming the involvement of VKORC1 in NAFLD in HepaRG cells Single sgRNA transductions were performed as previously described, and HepaRG cells were selected on either BFP expression (for mRNA isolation) or puromycin resistance using (for confocal microscopy. sgRNAs were either targeting VKORC1, or were non-targeting sgRNAs as control. Cells were cultured either on standard 6-well plates (mRNA) or in confocal compatible cell culture chambers. After 10 days of gene-editing, double positive (BFP and mCherry) HepaRG cells were sorted, and total mRNA was isolated using Qiagen kits according to the manufacturer's instructions. mRNA was reversely transcribed using a High-Capacity cDNA Reverse Transcription kit (Thermofisher), qPCR using TaqMan

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

10

Data were downloaded as per GEO instructions, and VKORC1 expression was assessed in relation to the

available metadata on steatosis grade, NAFLD activity score, and inflammation. Expression levels were extracted using R version 4.3.1, and later plotted in GraphPad Prism v.9. PheWAS and eQTL analyses in public databases The global biobank engine was used to explore the lead NAFLD-S SNP (rs9934438) in relation to other cardiometabolic traits (Global Biobank Engine, Stanford, CA (http://gbe.stanford.edu) [12, 2023]). The adapted to explore eQTL effects of rs9934438, **GTEx** database was (GTEx Portal [https://gtexportal.org/home/] on 12/11/23). Statistical analyses All statistical analyses pertaining the generation of the NAFLD score were carried out in R 3.5.1 using the pROC package. Plotting of GWAS results was also carried out using R. Plink v.2 was used for genetic analyses. Single-cell RNA-seq data comparing proliferative and differentiated HepaRG cells were analysed using Seurat, and the 'FindMarkers' differential expression analysis function using Wilcoxon tests. Unsupervised clustering based on single-cell transcriptomes was carried out for both differentiated and undifferentiated HepaRG cells. For each cluster, the top 20 upregulated genes in that cluster were input into GSEA pathway enrichment analyses using 'Hallmark genes', 'Gene Ontology' and 'Reactome' pathways. The scMAGeCK package was used to explore differential expression produced by sgRNA perturbations. Differentially expressed genes (comparing targeting vs. non-targeting sgRNAs) from scMAGeCK analyses were input into GSEA pathway enrichment analyses. Functional experimental data were plotted and analysed using GraphPad Prism v. 9. Student's T-test, or ANOVA with post-hoc test was applied as appropriate on data passing Shapiro-Wilk's test for normality, otherwise non-parametric tests were applied.

Results

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

12

visualized by scaled y-axes on Manhattan plots, and the three association studies plotted in the same Q-Q

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

13

(n=XXX genes). This provides a rationale for using composite surrogate variables for GWAS of NAFLD

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

14

metabolism while suppressing proliferation. Clustering of single-cells showed that there are no significant

differences between wild-type (Wt) and genetically engineered dCas9-KRAB-HepaRG cells, *Figure 3B*, and thus, all cells were analyzed jointly.

Clustering with regard to single-cell transcriptomes of Wt and dCas9-KRAB HepaRG cells revealed 11 distinct clusters; clusters 1, 3 and 5 belong to undifferentiated cells, whereas the remaining clusters belong to differentiated HepaRG cells. Genes involved in the cell cycle, G2M checkpoint, EMT and cell division are all more highly expressed in the undifferentiated clusters. In contrast, genes involved in drug metabolizing pathways, lipid metabolism, hemostasis and albumin are significantly upregulated in differentiated cells, particularly in clusters 0, 2, 4, 6 and 9, *Figure 3C-D*, *Supplementary Table 6*. It is expected that numerous cells undergo apoptosis during the differentiation process. In line with this, cells within clusters 8 and 10 express genes involved in apoptosis, p53 and programmed cell death, *Figure 3D*, *Supplementary Table 6*. Cells within cluster 7 seem to consist of a population of cells that may not be fully differentiated, as they highly express some hepatocyte and proliferative markers, *Figure 3D* and *Supplementary Table 6*. In summary, HepaRG cells are efficiently differentiated to a hepatocyte-like phenotype as the transcriptome of the cells belonging to clusters 4, 6, 7, 9 (>50% of cells) indicate a shift consistent with hepatocyte biology and function.

Differentiated and proliferative HepaRG cells cluster separately, as shown in **Figure 3E**. We compared the differentiated and undifferentiated cell populations based on a list of hepatocyte markers and the human liver atlas (28), regardless of their dCas9-KRAB status. Differentiated cells demonstrate an increased expression of hallmark hepatocyte genes including *ALB*, *CYP3A4*, *HP*, and *DPP4*, *Figure 3F*. The expression of a list of hepatocyte genes involved in drug and lipid metabolism were also increased compared to undifferentiated cells, *Figure 3G*. Next, we analyzed global differential gene expression. Gene set enrichment analysis revealed that differentiated HepaRG cells increase their expression of genes involved in metabolic processes; both in lipid metabolism and the genes within drug metabolism, *Figure 3H*, *Supplementary Figure 3A-B*, and *Supplementary Table 7*.

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

16

CRISPRi screen and Perturb-seq implicates putative causal genes in NAFLD We created a combinatory lipid accumulation-based CRISPRi and Perturb-seg screen in the dCas9-KRAB-HepaRG cell system to investigate putative NAFLD genes. We optimized the lipid accumulation-based CRISPRi system by knocking down the lipid droplet associated protein PLIN2 to markedly reduce lipid accumulation. dCas9-KRAB-HepaRG cells were transduced with three sgRNAs targeting PLIN2 along with a non-targeting sgRNA as a control, loaded with 400uM oleic acid for 24hrs. Next, neutral lipids were stained using Bodipy. Lipid loading was significantly increased after 24hrs of oleic acid treatment, and the efficiency of the sgRNAs was confirmed, Figure 4A-C. mCherry/BFP+/+ HepaRG cells were sorted with regard to lipid content after 10 days of gene-editing, and gDNA was isolated in the most and least lipidladen cells (the 20th percentile in either tail), *Figure 4D-E*. Sequencing of gDNA from the most and least of lipid loaded HepaRG cells, as measured by Bodypi staining, revealed a significant enrichment of PLIN2 sgRNAs in the least lipid-laden cells, indicating that *PLIN2* knockdown indeed impairs lipid accumulation, Figure 4F-G. This experiment served as a proof-of-principle for our CRISPRi screen, which included sgRNAs targeting a small selection of putative NAFLD genes, selected based on our human molecular genetic analyses. Eleven known and putative NAFLD genes were selected for tandem CRISPRi and Perturb-seq to explore their role in NAFLDNAFLD development, as measured by HepaRG lipid accumulation and single-cell transcriptional changes. The genes were selected based on 1) their robustness of association to NAFLD NAFLD (amount of evidence if known NAFLD gene), 2) emerging evidence for an association without functional validation, and 3) new association with NAFLD-S that also demonstrates association to other cardiometabolic traits. The genes can be found in Table 2. Next, sgRNAs directed towards selected NAFLD genes were transduced in differentiated dCas9-expressing HepaRG cells for a tandem CRISPRi and Perturb-seq experiment *Figure 5A*.

In parallel to the lipid accumulation-based CRISPRi screen, we produced single-cell transcriptomes from all perturbations. The experiment was performed in a total of five 10X Genomics single-cell captures, from two biological replicates. Single-cell transcriptomes were analyzed using Seurat, and the general quality control data is visualized in *Supplementary Figure 3A*. While there was no clustering by replicate or sgRNA identity, perturbations produced by the sgRNAs are consistently efficient and specific as only the intended target gene is significantly knocked down, *Figure 5C-E. VKORC1* knockdown produced the most striking transcriptional changes, and will be discussed in detail below. *GPAM* knockdown resulted in a downregulation of genes enriched in oxidative phosphorylation and RNA transcription pathways, while the upregulated genes were enriched in pathways pertaining cellular stress, glycolysis, apoptosis and cell cycle, *Supplementary Table 8*. *LYPLAL1* knockdown resulted in the downregulation of genes involved in interferon-response, adipogenesis, and oxidative phosphorylation, amongst others. Genes upregulated by *LYPLAL1* knockdown are enriched in metabolism of heme and blood vessel formation, *Supplementary Table 8*. We found pathway enrichments in adipogenesis, HDL, and chylomicron metabolism, and estrogen response among genes downregulated upon *TNKS* knockdown. Differential gene expression for all perturbations are visualized as heatmaps in *Supplementary Figure 4*, and *Supplementary Table 8*.

While we decided to focus on the target gene VKORCI – because of its novelty and significant impact on lipid accumulation – we validate one gene (GPAM) influencing lipid accumulation in the opposite direction to VKORCI. We knocked down GPAM using single sgRNA transductions, and recapitulated the findings

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

18

Figure 6A. We investigate gene set enrichment of all VKORC1 interactors, and enrichments were found

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

19

in processes pertaining lipid homeostasis, oxidoreductase activity, lipid metabolic processes, and sterol homeostasis, Supplementary Table 11. We next performed knockdown experiments of VKORC1 in HepaRG cells using single sgRNA transductions to confirm our observations from single-cell CRISPRi screens, with a non-targeting sgRNA as control. The knockdown was confirmed using RT-qPCR against VKORC1, Figure 6A. We recapitulated the in vitro phenotype observed in the single-cell CRISPRi screens, where the reduction of VKORCI expression brought about a reduction in PLIN2 expression, accompanied by a reduction in lipid accumulation as measured by Bodipy using flow cytometry and confocal microscopy, Figure 6B-E. To better understand the role of VKORC1 expression in human NAFLD, we investigated publicly available data on VKORCI transcript levels in a cohort of 78 human livers encompassing the entire spectrum of NAFLD. Our analyses show a positive association of NAFLD activity score, steatosis, and inflammation with VKORC1 expression, Figure 6F-H. These data suggest that VKORC1 is involved in the initiation of NAFLD, however, VKORC1 does not seem to the primary driver of the progression of disease as transcript levels only increase over the lowest grade of disease, and not as grades of disease progress. We explored the co-expression patterns of VKORC1 and transcripts of a selection of genes involved in lipid metabolism and fibrosis that are thought to drive disease progression in healthy human liver, the ASAP study. Co-expression patterns revealed that VKORC1 expression correlates with the expression of genes involved in uptake of lipids, as well as in intracellular fatty acid and triglyceride synthesis. Further, VKORC1 mRNA levels are correlated with transcript levels of collagen and TGFβ, which are genes known to promote fibrosis, Supplementary Figure 7A. VKORC1 was negatively correlated with genes involved in the mobilization of lipids from hepatocytes; MTTP and SREBF1, suggesting that VKORC1 expression promotes the intracellular accumulation of lipids in human liver.

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

20

data suggest that VKORC1 expression is associated with the increase in intracellular accumulation of lipids,

and thereby drive the intiation of NAFLD development. Investigations can now be expanded to interrogate

a large selection of putative causal NAFLD genes to further determine the molecular landscape of disease development and progression.

Discussion

In the present study we generate a NAFLD-S that outperforms single variable surrogates when validated against 'ground truth' NAFLD as defined by >5.5% liver fat obtained from proton density fat fraction from MRI images in the UKB. By using a new surrogate marker of NAFLD for our GWAS, together with colocalization analyses of previous GWAS, we expand the knowledge on the genetic susceptibility to NAFLD. We create a functional genomic framework to validate putative NAFLD genes and explore the role of a subset of genes on hepatocyte lipid accumulation, single-cell transcriptomes, and murine and human disease.

GWAS have been useful in the identification of common susceptibility variants for various cardiometabolic traits. However, GWAS for NAFLD have remained small and underpowered, and therefore, surrogate markers of NAFLD have been extensively used, all with their strengths and drawbacks. The FLI does not seem to outperform waist circumference in predicting NAFLD (4), NAFLD may be present without ALT elevation (29,30), and high ALT levels could reflect a myriad of liver insults. Thus, FLI and ALT may constitute poor surrogates for NAFLD. Our NAFLD-S might not only reflect metabolic liver disease, but also an insulin resistance phenotype as the score takes into account waist circumference, BMI, HbA1c and triglyceride levels, which are all also associated with insulin resistance. By integrating anthropometric and biochemical data into a single score, we sought to capture the global etiology of NAFLD given its correlation with dyslipidemia, type II diabetes, and obesity. We outperform ALT levels in predicting liver fat in the UKB, however, mitigation of the drawbacks of using ALT measurements as surrogate for NAFLD could be achieved by using chronic ALT elevation, which has been described elsewhere. (24) We find several overlaps in the genetic colocalizations between several NAFLD surrogates, which suggests that

these surrogates capture a common part of the disease etiology, but also may reflect different aspects of the natural history of NAFLD.

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

We created a HepaRG cell model system suitable for large-scale CRISPRi screening and Perturb-seq to explore putative NAFLD genes. We selected a group of both previously associated (PNPLA3, TNKS/PPP1R3B, GPAM, LYPLAL1, TRIB1) and novel or less established (WDR6, VKORC1, RBM6, NCKIPSD, C6orf106) NAFLD candidate genes to establish a functional genetic framework to interrogate new potential disease genes at scale. We screened the selected genes for their influence on hepatocyte lipid accumulation in our in vitro gene-editing system, and generated single-cell transcriptomes for these CRISPR-based knockdown perturbations. Our data suggest the involvement of VKORC1 and TNKS (increased lipid content), LYPLAL1 and GPAM (decreased lipid content) on lipid accumulation in hepatocytes, which we further validated for VKORC1 and GPAM. The latter is a well-established NAFLD locus, and its knockdown resulted in increased lipid accumulation in HepaRG cells. In contrast, VKORC1 knockdown resulted in less lipid accumulation, possibly mediated by lower PLIN2 levels. The knockdown of VKORC1 also resulted in the perturbation of the transcriptional landscape of lipid metabolism, and insulin resistance genes like PLIN2, PNPLA2, G6PC, and INSR were dysregulated. Finally, we explored the mRNA expression of VKORC1 in a murine model and human disease, where VKORC1 expression consistently was increased upon high-fat diet. We strengthen the notion that low VKORCI expression may be protective of disease development, by exploring the expression levels in relation to the degree of steatosis, NAFLD activity score, and inflammation. By using human molecular genetics, we demonstrated that the NAFLD-S lowering SNP rs9934438 also improves other anthropometric and biochemical cardiometabolic traits, while lowering the expression of the VKORC1 transcript. Collectively, this suggests a protective role of low *VKORC1* expression in NAFLD.

VKORC1 is known to reduce vitamin K to its active form, which promotes the formation of functional clotting factors from pro-clotting factors. This process is inhibited by warfarin and ultimately results in

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

VKORC1 as a NAFLD susceptibility gene.

Limitations

577

578

579

580

581

582

583

584

585

586

587

591

592

- This work was conceived and primarily executed before the change in nomenclature from NAFLD to
- MASLD. The authors have after consideration opted to retain the old nomenclature in this manuscript as
- data referenced herein were generated under these guidelines.

References

- Shang Y, Nasr P, Widman L, Hagström H. Risk of cardiovascular disease and loss in life expectancy in NAFLD. Hepatology. 2022;
- Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, et al. Nonalcoholic Fatty Liver
 Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association.
 Arterioscler Thromb Vasc Biol. 2022;42:e168–e185.
- Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver
 Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC
 Gastroenterol. 2006;6:33.
- Motamed N, Sohrabi M, Ajdarkosh H, Hemmasi G, Maadi M, Sayeedian FS, et al. Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease. World J Gastroenterol. 2016;22:3023–3030.
- 5. Datlinger P, Rendeiro AF, Schmidl C, Krausgruber T, Traxler P, Klughammer J, et al. Pooled CRISPR screening with single-cell transcriptome readout. Nat Methods. 2017;14:297–301.

- 60. Replogle JM, Norman TM, Xu A, Hussmann JA, Chen J, Cogan JZ, et al. Combinatorial single-cell CRISPR screens by direct guide RNA capture and targeted sequencing. Nat Biotechnol.
- 608 2020;38:954–961.
- 7. Replogle JM, Bonnar JL, Pogson AN, Liem CR, Maier NK, Ding Y, et al. Maximizing CRISPRi
- efficacy and accessibility with dual-sgRNA libraries and optimal effectors [Internet]. 2022 [cited
- 611 2022 Jul 28];2022.07.13.499814. Available from:
- https://www.biorxiv.org/content/10.1101/2022.07.13.499814v1
- 8. Replogle JM, Saunders RA, Pogson AN, Hussmann JA, Lenail A, Guna A, et al. Mapping
- information-rich genotype-phenotype landscapes with genome-scale Perturb-seq. Cell.
- 615 2022;185:2559-2575.e28.
- 9. Morgens DW, Deans RM, Li A, Bassik MC. Systematic comparison of CRISPR/Cas9 and RNAi
- screens for essential genes. Nat Biotechnol. 2016;34:634–636.
- 618 10. Schnurr TM, Katz SF, Justesen JM, O'Sullivan JW, Saliba-Gustafsson P, Assimes TL, et al.
- 619 Interactions of physical activity, muscular fitness, adiposity, and genetic risk for NAFLD. Hepatol
- 620 Commun. 2022;6:1516–1526.
- 621 11. European Association for the Study of the Liver (EASL), European Association for the Study of
- Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO
- 623 Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol.
- 624 2016;64:1388–1402.
- 625 12. UK Biobank UK Biobank [Internet] [Internet]. [cited 2022 Jul 27]. Available from:
- https://www.ukbiobank.ac.uk/
- 627 13. Benner C, Spencer CCA, Havulinna AS, Salomaa V, Ripatti S, Pirinen M. FINEMAP: efficient
- variable selection using summary data from genome-wide association studies. Bioinformatics.
- 629 2016;32:1493–1501.
- 630 14. Hormozdiari F, van de Bunt M, Segrè AV, Li X, Joo JWJ, Bilow M, et al. Colocalization of GWAS
- and eQTL Signals Detects Target Genes. Am J Hum Genet. 2016;99:1245–1260.
- 15. Gloudemans MJ, Balliu B, Nachun D, Durrant MG, Ingelsson E, Wabitsch M, et al. Integration of
- genetic colocalizations with physiological and pharmacological perturbations identifies
- cardiometabolic disease genes [Internet]. 2021 [cited 2022 Feb 20];2021.09.28.21264208. Available
- from: https://www.medrxiv.org/content/10.1101/2021.09.28.21264208v1
- 636 16. Parent R, Marion M-J, Furio L, Trépo C, Petit M-A. Origin and characterization of a human bipotent
- liver progenitor cell line. Gastroenterology. 2004;126:1147–1156.
- 638 17. Parent R, Beretta L. Translational control plays a prominent role in the hepatocytic differentiation of
- HepaRG liver progenitor cells. Genome Biol. 2008;9:R19.
- 18. Marion M-J, Hantz O, Durantel D. The HepaRG cell line: biological properties and relevance as a
- tool for cell biology, drug metabolism, and virology studies. Methods Mol Biol. 2010;640:261–272.

- Hart SN, Li Y, Nakamoto K, Subileau E, Steen D, Zhong X. A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues. Drug Metab Dispos. 2010;38:988–994.
- Gilbert LA, Horlbeck MA, Adamson B, Villalta JE, Chen Y, Whitehead EH, et al. Genome-Scale
 CRISPR-Mediated Control of Gene Repression and Activation. Cell. 2014;159:647–661.
- Tanigawa Y, Li J, Justesen JM, Horn H, Aguirre M, DeBoever C, et al. Components of genetic
 associations across 2,138 phenotypes in the UK Biobank highlight adipocyte biology. Nat Commun.
 2019;10:4064.
- 450 22. Horlbeck MA, Gilbert LA, Villalta JE, Adamson B, Pak RA, Chen Y, et al. Compact and highly
 active next-generation libraries for CRISPR-mediated gene repression and activation. Elife.
 452 2016;5:e19760.
- Pazoki R, Vujkovic M, Elliott J, Evangelou E, Gill D, Ghanbari M, et al. Genetic analysis in
 European ancestry individuals identifies 517 loci associated with liver enzymes. Nat Commun.
 2021;12:2579.
- Vujkovic M, Ramdas S, Lorenz KM, Guo X, Darlay R, Cordell HJ, et al. A multiancestry genome wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver
 disease with histological and radiological validation. Nat Genet. 2022;54:761–771.
- Miao Z, Garske KM, Pan DZ, Koka A, Kaminska D, Männistö V, et al. Identification of 90 NAFLD
 GWAS loci and establishment of NAFLD PRS and causal role of NAFLD in coronary artery disease.
 HGG Adv. 2022;3:100056.
- Graham SE, Clarke SL, Wu K-HH, Kanoni S, Zajac GJM, Ramdas S, et al. The power of genetic diversity in genome-wide association studies of lipids. Nature. 2021;600:675–679.
- 27. Rask-Andersen M, Karlsson T, Ek WE, Johansson Å. Genome-wide association study of body fat distribution identifies adiposity loci and sex-specific genetic effects. Nat Commun. 2019;10:339.
- 28. Aizarani N, Saviano A, Sagar null, Mailly L, Durand S, Herman JS, et al. A human liver cell atlas reveals heterogeneity and epithelial progenitors. Nature. 2019;572:199–204.
- Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty
 liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–
 1419.
- 30. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994;107:1103–1109.
- 31. Li T, Chang C-Y, Jin D-Y, Lin P-J, Khvorova A, Stafford DW. Identification of the gene for vitamin
 K epoxide reductase. Nature. 2004;427:541–544.
- 32. Assy N, Bekirov I, Mejritsky Y, Solomon L, Szvalb S, Hussein O. Association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases. World J Gastroenterol. 2005;11:5834–5839.

Kotronen A, Joutsi-Korhonen L, Sevastianova K, Bergholm R, Hakkarainen A, Pietiläinen KH, et al.
 Increased coagulation factor VIII, IX, XI and XII activities in non-alcoholic fatty liver disease. Liver
 International. 2011;31:176–183.

- 34. Di Minno MND, Tufano A, Rusolillo A, Di Minno G, Tarantino G. High prevalence of nonalcoholic fatty liver in patients with idiopathic venous thromboembolism. World J Gastroenterol.
 2010;16:6119–6122.
- Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hörtnagel K, Pelz H-J, et al. Mutations in
 VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature.
 2004;427:537–541.
- 36. Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood.
 2008;112:1022–1027.
- 37. Bielczyk-Maczynska E, Sharma D, Blencowe M, Gustafsson PS, Gloudemans MJ, Yang X, et al.
 CROP-Seq: a single-cell CRISPRi platform for characterizing candidate genes relevant to metabolic disorders in human adipocytes [Internet]. 2022 [cited 2023 Jul 5];2022.06.27.497796. Available from: https://www.biorxiv.org/content/10.1101/2022.06.27.497796v1

Acknowledgements

694

695

699

700

701

702

703

704

705

706

707

- The authors would like to express their gratitude to all funding bodies contributing to this work, as well as
- Drs. Frank Chenfei Ning and Annelie Falkevall for generously providing liver cDNA samples from mice
- on high fat and chow diet.

Figure legends

Figure 1 Human molecular genetic analyses in the UK Biobank. Non- or moderately drinking European ancestry British participants were selected for the analyses. **A)** ROC curve showing the predictive power of NAFLD-S and individual biochemical and anthropometric variables on NAFLD status as defined by liver fat > 5.5% in UK biobank. **B)** Manhattan plot for the genome-wide association study on NAFLD defined as >5.5% liver fat in UK biobank. **C)** Genome-wide association study on NAFLD score in UK biobank, visualized using a Manhattan plot. **D)** ALT associations from the genome-wide association study in UK biobank, visualized by a Manhattan plot. **E)** Q-Q plot for the GWA studies on

Y-axes in Manhattan plots are scaled for comparison between the three association studies.

Figure 2 Colocalization study of NAFLD-S associated SNPs in the UK Biobank. A) Strategy for genetic colocalization studies to infer causality of novel putative NAFLD genes found from GWAS with metabolically active tissues in the GTEx (v8) database. Liver enzymes include ALT, ALP, GGT and qnormALT_UKB, MRI/ML MRI_UKB and machine-learning MRI, NAFLD-S out novel NAFLD score and the NAFLD score from Miao et al. B) Overlap of genes with a significant liver eQTL/sQTL colocalization. GSEA gene set enrichment analysis of colocalized genes can be found in Table 2. Full list of colocalizations can be found in Supplementary Table 5.

Figure 3 Characterisation of a HepaRG model system that is genetically engineered to allow for CRISPRi gene-editing. A) Description of HepaRG culturing, indicating at which point scRNA-seq was used to characterize the model system. B) Clustering by both genotype and differentiation stage (temporal analysis along the differentiation axis). Data demonstrate that cells efficiently differentiate regardless of genotype (dCas9-KRAB integration) and that cells remain in their differentiated phenotype two weeks after differentiation is complete. This allows for gene-editing after complete HepaRG differentiation. C) Clustering of scRNA-seq data, where proliferative and differentiated cells are plotted together, irrespective of genotype (dCas9-KRAB integration). Data show 11 different clusters divided over two distinct populations of cells. D) Differential gene expression analyses based on clustering in Figure 3B. Clusters 1, 3 and 5 belong to undifferentiated cells, whereas the remaining clusters belong to the differentiated HepaRG cells; genes involved in drug metabolizing pathways, lipid metabolism, hemostasis and albumin were significantly upregulated in differentiated cells, particularly in clusters 0, 2, 4, 6 and 9. Lists for differentially expressed genes can be found in Supplementary Table 6. E) Clustering by differentiation status irrespective of genotype. Data demonstrate a perfect clustering of HepaRG cells by their differentiation status. F) Expression of hepatocyte hallmark genes ALB,

Differential expression analyses of genes suggested to define hepatocytes from 'the human liver atlas'.

Data show that the transcriptional program thought to define hepatocytes is enhanced upon

differentiation. H) Global differential expression analyses by differentiation status. Genes upregulated

by differentiation are enriched in processes related to small molecule and lipid metabolic processes,

mitochondrial processes and electron transport chain, Supplementary Table 10. Complete lists of

differentially expressed genes can be found in Supplementary Table 7.

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

Figure 4 Establishment of, and control experiments in a HepaRG cell CRISPRi gene-editing model system with lipid accumulation as readout. A) Micrographs showing that lipid loading using 400 µM of oleic acid results in significant formation of large lipid droplets. B) Lipid loaded HepaRG cells were stained with 1 µg/ml Bodipy and analysed using flow cytometry. Data show that lipid loading (Blue histogram) increases the content of neutral lipids within the HepaRG cell compared to non-loaded control cells (Red histogram). C) PLIN2 was knocked down as a proof-of-principle experiment. PLIN2 expression was efficiently silenced in our dCas9-KRAB expressing HepaRG cells, and sgRNAs from the v2 Weissman library. D) Representative gates for sorting gene-edited HepaRG cells (blue), and an untransduced control, negative for both mCherry and BFP (red). The Q2 gate contains the gene-edited cells, which express dCas9-KRAB, and have been efficiently transduced with sgRNAs. E) Gene-edited HepaRG cells from Q2 were sorted based on their Bodipy content; approximately the top and bottom 18% of cells were sorted, and gDNA was prepared from both extreme populations. gDNA was then sequenced using NGS. F-G) By assessing the enrichment of PLIN2 sgRNAs in the cell population with the least intracellular lipids, we find a 2-3 times enrichment of PLIN2 sgRNAs compared to nontargeting sgRNAs. As one would expect, these data demonstrate hampered lipid accumulation in HeapRG cells that do not express PLIN2. The casTLE pipeline was also piloted for this purpose, and analysed data recapitulates simple sgRNA counting and fold change calculations in that we show a 2 times enrichment of PLIN2 sgRNAs in the least lipid laden cells compared to what one would expect

lipid accumulation in HepaRG cells, and show that appropriate analysis methods are employed.

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

Figure 5 Tandem lipid-based CRISPRi and Perturb-seq in HepaRG cells to explore the involvement of genes, suggested from human molecular genetics, in NAFLD pathogenesis. A) Experimental outline of tandem CRISPRi and Perturb-seq in HepaRG cells. HepaRG cells were harvested on day 42 of culturing, as per the protocol described in Figure 3A. B) Volcano plot, following sequencing of gDNA in the most and least lipid laden HepaRG cells, where casTLE effect and score are plotted against each other. Data demonstrate that knockdown of VKORC1 and TNKS results in less intracellular lipids. Conversely, knockdown of genes *GPAM* and *LYPLAL1* increases intracellular lipids. **C-D)** Perturb-seq is performed in parallel to our lipid accumulation-based CRISPRi to explore the transcriptomic profiles resulting from a gene knockdown. No major changes in clustering of gene-edited cells by replicate and sgRNA identity is observed. Data show that replicates are very similar, and sgRNAs have modest effects on the transcriptome that causes the cells to cluster separately. E) Dotplot visualizing that the knockdown of sgRNAs targeting the selected genes is efficient and specific as demonstrated by the blue dots along the diagonal. **F-G**) Differential gene expression analyses upon VKORC1 knockdown are carried out using the scMaGeCK R-package, and differentially expressed genes are plotted in a representative heatmap. Results reveal that VKORC1 knockdown changes the transcriptional landscape, and reduces the gene expression of genes involved in lipid metabolism, Golgi and ER, as well as homeostatic processes. Complete results of differentially expressed genes for all perturbations can be found in Supplementary Figure 4, and Supplementary Table 8.

Figure 6 Validation experiments of VKORC1 knockdown in differentiated HepaRG cells, and the relationship between VKORC1 transcript and human disease. A) Single sgRNA knockdown of VKORC1 in differentiated HepaRG cells results in a significant knockdown of the VKORC1 transcript as measured by qPCR. Concomittant with VKORC1 knockdown, we demonstrate a significant

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

downregulation of the PLIN2 transcript. **B-C**) VKORC1 knockdown results in reduction of intracellular neutral lipids by Bodipy staining and flow cytometric analysis. D-E) Confocal microscopy of HepaRG cells upon VKORC1 knockdown shows a significant reduction in Bodipy neutral lipid staining; lipid droplet number, lipid droplet area, as well as PLIN2 positive area. F-H) By exploring VKORC1 expression levels in different stages of human disease we demonstrate an upregulation of the VKORC1 transcript in livers of a higher degree of NAFLD activity score, steats is, and inflammation. N for experimental data is 6-7 replicates, Ordinary one-way ANOVA was performed to compare the nontargeting sgRNA with the VKORC1 targeting sgRNAs. Total n for human liver samples is 78. * p < 0.05, ** *p*<0.01, ****p*<0.001, *****p*<0.0001. Supplementary Figure 1 Clustering of HepaRG scRNA-seq characterization experiments. Each genotype and culturing day along the differentiation process was plotted separately. Notably, we observe no major differences in the clustering by genotype or differentiation day (28 days or 42 days post seeding)

as shown by Figure 3B. Micrographs showing the gross phenotype of differentiated HepaRG, as has been previously described.

Supplementary Figure 2 Standard scRNA-seq quality control. Cells exhibiting less than 200 detected features, 2000 RNAs and more than 25% mitochondrial genes (justified based on high expression of mitochondrial genes in differentiated HepaRG cells) were filtered out.

Supplementary Figure 3 Standard scRNA-seq quality control was carried out on HepaRG cells undergoing Perturb-seq. As before, cells exhibiting less than 200 detected features, 2000 RNAs and more than 25% mitochondrial genes were filtered out.

Supplementary Figure 4 Heatmaps of differentially expressed genes by all targets in Perturb-seq experiments. GPAM and LYPLAL1 are the two top targets after VKORC1 based on their effects on lipid

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837


32

induce hepatic steatosis, demonstrate a higher expression of Vkorc1 along with increased Plin2 mRNA.

N for experimental data is 6-11 replicates. * p<0.05, ** p<0.01, ***p<0.001, ****p<0.001.


Supplementary Figure 8 Exploration of the VKORC1 locus, and associations with other cardiometabolic traits using PheWAS. A) Correlation plot between NAFLD-S GWAS p-values and GTEx (v8) liver eQTL p-values, as well as locus plots for NAFLD-S associations and eQTL effects plotted separately, in SNPs used for VKORC1 colocalization. B) PheWAS analysis of the NAFLD-S lead SNP rs9934438, and its association with cardiometabolic traits. Notably, the rs9934438 A allele is associated with lower hip and waist circumference, lower BMI and lower values for several fat mass phenotypes in the Biobank engine powered by Stanford University. Furthermore, the rs9934438 A allele is also associated with lower levels of biomarkers of cardiometabolic disease (ApoB, TG, HbA1c), and higher levels of protective biomarkers (HDL, ApoA). C) Importantly, the rs9934438 A allele that is associated with protection from NAFLD-S and cardiometabolic biomarkers, and is associated with more protective biomarkers of cardiometabolic disease is also associated with lower VKORC1 expression. This suggests that lower VKORC1 expression in the liver may protect from protective of NAFLD and cardiometabolic disease.

Functional genomic framework to elucidating novel causal NAFLD genes



859

Figure 1







Figure 3









Figure 5












Supplementary Figure 2

Standard scRNA-seq QC employed



Supplementary Figure 3

